Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19718558 | 0.87 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1CA12CA1CA2 | |
| SCHEMBL11845550 | 0.87 | SMN1; SMN2 (0.73) | SMN1; SMN2ALDH1A1CA12CA1CA2 | |
| SCHEMBL21093408 | 0.86 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1CA12CA1CA2 | |
| SCHEMBL9717664 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2ALDH1A1CA12CA1CA2 | |
| SCHEMBL2224069 | 0.83 | CA12 (0.73) | SMN1; SMN2ALDH1A1CA12CA1CA2 | |
| SCHEMBL10359474 | 0.83 | CA12 (0.73) | SMN1; SMN2ALDH1A1CA12CA1CA2 | |
| SCHEMBL8099685 | 0.83 | CA1 (0.73) | SMN1; SMN2ALDH1A1CA12CA1CA2 | |
| SCHEMBL901614 | 0.83 | CA12 (0.73) | SMN1; SMN2ALDH1A1CA12CA1CA2 | |
| SCHEMBL7265002 | 0.83 | CA12 (0.73) | SMN1; SMN2ALDH1A1CA12CA1CA2 | |
| SCHEMBL1917292 | 0.82 | MAPT (0.84) | SMN1; SMN2ALDH1A1MAPTKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046620-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046620-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | CRY1, DDT, CYC1 | SMN1; SMN2 262/4885ALDH1A1 2272/4885CA12 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.